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Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most
common genetic renal disorder caused by mutation in 2 genes PKD1 and PKD2. Thus
far, no mutation is identiﬁed in approximately 10% of ADPKD families, which can
suggest further locus heterogeneity. Owing to the complexity of direct mutation
detection, linkage analysis can initially identify the responsible gene in appropriate
affected families. Here, we evaluated an Iranian ADPKD family apparently unlinked
to both PKD1 and PKD2 genes. This is one of the pioneer studies in genetic analysis
of ADPKD in Iranian population.
Methods: Linkage reanalysis was performed by regenotyping of ﬂanking micro-
satellite markers in 8 individuals of the ADPKD family. Direct mutation analysis was
performed by Sanger sequencing.
Results: Mutation analysis revealed a pathogenic mutation (c.1094þ1G>A) in the
PKD2 gene in the proband. Analyzing 2 healthy and 4 clinically affected members
conﬁrmed the correct segregation of the mutation within the family and also ruled
out the disease in 1 suspected individual. Misinterpretation of the linkage data was
due to the occurrence of 1 crossing over between the PKD2 intragenic and the
nearest downstream marker (D4S2929). Homozygosity of upstream markers caused
the recombination indistinguishable.
Conclusion: Although analysis of additive informative polymorphic markers can
overcome the misleading haplotype data, it is limited because of the lack of other
highly polymorphic microsatellite markers closer to the gene. Direct mutation
screening can identify the causative mutation in the apparently unlinked pedigree;
moreover, it is the only approach to achieve the conﬁrmed diagnosis in individuals
with equivocal imaging results.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).dical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
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Autosomal dominant polycystic kidney disease (ADPKD
[OMIM# 173900]) is the most common genetic renal disorder,
affecting approximately 1 in 400 to 1,000, in different pop-
ulations [1,2]. It is characterized by renal and extrarenal man-
ifestations including bilateral renal cysts; hypertension; cysts in
the liver, seminal vesicles, pancreas, and arachnoid membrane;
intracranial aneurysms; dilatation of the aortic root; and mitral
valve prolapse.
ADPKD is a genetically heterogeneous disorder with 2
known causative genes, PKD1 (MIM# 601313) on chromosome
16p13.3 [3] and PKD2 (MIM# 173910) on chromosome 4q21-23
[4], both discovered through linkage analysis. However, some
reported families unlinked to either of these genes, suggesting
the existence of a third locus [5e8]; likewise, no mutation is
identiﬁed in approximately 10% of ADPKD families [9]. More
investigations revealed cosegregation of both PKD1 and PKD2
mutations in 1 previously unlinked family [10]. Besides, a
recent comprehensive study identiﬁed pathogenic mutations
in 4 of 5 such families [11]. Although these ﬁndings reduce the
possibility of the third PKD3 locus, they highlight the impor-
tance of considering the linkage and haplotype segregation
analysis confounders.
Linkage or haplotype analysis has been used widely in a
variety of molecular genetics investigations, including genetic
diagnosis, population genetics, forensics, complex kinship
analysis, and also transplantation medicine [12e14]. Further-
more, it is an efﬁcient approach to determine the pattern of
inheritance among generations using highly polymorphic
markers, mainly in the case of heterogeneous and multigenic
disorders.
Although the new emerging next-generation sequencing
method is the best and comprehensive method, it may not be
available or cost beneﬁt for research all over the world.
DNA testing is the deﬁnite ADPKD diagnostic method,
especially in patients with equivocal imaging ﬁndings, or very
early-onset cases, as well as potential related kidney donors
from affected families. Also it helps at-risk couples to prevent
disease transmission using preimplantation genetic diagnosis
(PGD). In regard to emerging new therapeutic drugs, genetic
testing might help to predict the best time and person to
receive the intervention [15].
This study is one of the pioneer studies in genetic analysis of
ADPKD in Iranian population, which investigates 1 IranianTable 1. Primer sequences for ampliﬁcation of PKD2 exons
Name Forward (50-30)
pkd2-E1 AGAGGGAGGCGGGCCAAAGG
pkd2-E2 ATTGCTAATGGGCTTGGGAGC
pkd2-E3 CAGAACAGGGCAGAGAAGAATGG
pkd2-E4 ATCATGACCCCACCTTTAGTCC
pkd2-E5 TCCCGAGTCTGCCCTCAAAAGC
pkd2-E6 GGAAGTACTCCTTTGGGACTGAA
pkd2-E7 AGCAGGATGAAGGCAAGAAAGC
pkd2-E8 AGCCATCGCCATTATGCTGCAT
pkd2-E9 GGAAATAACCTCTGTAGCATGAAAGC
pkd2-E10 GTCTTCATAAAGCACTCAGATTAGG
pkd2-E11-12 TGACTTACTGAAAGACCCTGAC
pkd2-E13 TAAATGGCATGCACCCAGTTCCT
pkd2-E14 TTCTGATACGCGCTGACTTGC
pkd2-E15 TGCTAATGGTCCTGCCTTCACTG
PKD, polycystic kidney disease.ADPKD family with excluded linkage to both PKD1 and PKD2
loci. Furthermore, herewe illustrated important sources of error
in linkage analysis, a basic method used in clinical laboratories.
Methods
Subjects and DNA extraction
All individuals of 1 ADPKD family (P-13), who showed no
linkage to both PKD1 and PKD2 loci in our previous study, were
recruited. New blood samples were collected from all available
individuals, including 5 patients, 2 healthy individuals, and 1
suspected patient with equivocal clinical diagnosis.
DNA was extracted using Exgene Blood SV mini kit (GeneAll
Biotechnology Co, Ltd, Seoul, Korea) according to the manu-
facturer's instruction. The quality and quantity of DNA were
assessed by the NanoDrop spectrophotometer (ND-1000,
Thermo Scientiﬁc, USA) as well as agarose gel electrophoresis.
The study was approved by the research ethics committee of
the Tehran University of Medical Sciences. Informed consent
was obtained from all the participants.
Analysis of microsatellite markers
Identiﬁcation of the haplotypes of all individuals was per-
formed manually based on the genotypes of 10 polymorphic
microsatellite markers within or around the PKD1 and PKD2
genes. Characteristics of microsatellite markers and ampliﬁca-
tion details were described previously [16]. Furthermore, an in-
house panel of 24 short tandem repeat markers was used to
investigate the paternity within the family.
PCR ampliﬁcation and sequencing
At the ﬁrst step, coding sequences and exoneintron
boundaries of PKD2 were screened by direct Sanger
sequencing. New primers were designed to amplify the PKD2
fragments with the average size of 600 bp (Table 1). All PKD2
exons, except exon 1, were ampliﬁed in a ﬁnal reaction volume
of 25 mL using polymerase chain reaction (PCR) Master Mix
(Ampliqon, Denmark, A140303) and 0.3 mmol/L of each primer,
along with 30 ng of DNA. The ﬁnal concentration of MgCl2 was
1.5 mmol/L. The cycling parameters were as follows: initial
denaturation of 95C for 5 minutes, followed by 30 cycles of
95C for 30 seconds, 61C for 30 seconds, 72C for 40 seconds,Reverse (50-30) Product size
CCGGAAATAGGGCAGCACTAGCG 929
AATTGAACTCTTTGCCTCTCCCG 765
GGCACAGGCAAAGTTCTCAATG 831
AGAAGTCAAAGGTCAAGTTGGC 738
CCTACTGAGCATCCTACAAGCACT 923
TTAGCGTGGCTGAGAGCATAC 689
GCTTTGGCTGGTCACTTGAATTTC 682
CTCAGTCTTCAGAACAGTGTTGGT 794
CATGGATCAATGAAAGACCACAGA 560
CGTGGAAGGTCAAGGGTAAAGG 680
GCAAGAGACTCAATAACCCACTAC 817
AGGAGTGAATTCAGAGAGATGAGGG 350
GTGAAGGCAGGACCATTAGCA 700
CAGTTAGTCCCACAGACATCAG 1,049
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higher GC content, ampliﬁcation of exon 1 was performed by
the addition of 1X Q-solution (Qiagen group, www.qiagen.com)
to the 25 mL reaction mixture as above, with denaturation at
98C for 5 minutes, followed by 40 cycles of 96C for 30 sec-
onds, 64C for 30 seconds, 72C for 40 seconds, and a ﬁnal
extension of 72C for 5 minutes.
PCR products were puriﬁed using the Expin kit (GeneAll
Biotechnology Co, Ltd) to improve the quality of sequencing.
Sanger sequencing was carried out using the ABI 3137 auto-
mated sequencer from Applied Biosystems (provided by the
PishgamBiotech Company, Tehran, Iran, www.pishgambc.com).Table 2. Mean heterozygosity and polymorphic information content
of each marker
Gene Marker MH PIC
PKD1 D16S3395 0.61 0.53
D16S3024 0.84 0.82
D16S3252 0.66 0.56
D16S664 0.49 0.46
PKD1-M1 0.71 0.66
PKD2 D4S2409 0.82 0.73
PKD2-M1 0.55 0.51
D4S2929 0.78 0.75
D4S1563 0.59 0.55
D4S2460 0.72 0.68
MH, mean heterozygosity; PIC, polymorphic information content; PKD,
polycystic kidney disease.
Figure 1. Pedigree and haplotype data of family P-13. Black boxes indicate th
suspected to be affected. Break in haplotype boxes shows the recombination p
PKD, polycystic kidney disease.Variant analysis
The quality of sequencing was checked through assessing
the obtained chromatogram by Sequence Scanner software,
version 1.0 (http://www.appliedbiosystems.com). The data
were then analyzed by Mutation Surveyor software, version
3.03 (www.softgenetics.com/mutationSurveyor.html), for
variation calling purposes. Pathogenesis potentiality of un-
classiﬁed variants was investigated by Sift, Provean [17], and
PolyPhen-2 [18] software. Segregation analysis was performed
by sequencing all the family members for the responsible
mutation.Results
Table 2 illustrates the polymorphic characteristics of each
marker.Mean heterozygosity of allmarkerswas higher than 0.5.
Pedigree structure of family P-13 is shown in Fig.1. The proband
(IV-1) was ﬁrst diagnosed with ADPKD at the age of 34 years by
regular ultrasound examination because of positive family his-
tory. Haplotypes were constructed for all individuals of the
family based on repeated microsatellite genotyping results. As
illustrated in Fig. 1, the linkage analysis of the PKD1 locus
identiﬁed that patients did not inherit the same haplotype. In
the case of PKD2 locus, all affected individuals share a
common haplotype, except IV-2 (diagnosed at age 22 by
regular ultrasound examination) and III-3. The ultrasound re-
sults and clinical investigations of the III-3 individual wase common PKD2 haplotype among affected individuals. Individual III-3 was
oint.
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posed to be affected because of her positive family history, so
she was excluded in the linkage analysis. Her ultrasound scan
revealed 1 small cyst in her right kidney that measured about
26 mm in the axial plane along with a small calciﬁed region.
Although noninformativeness of microsatellite markers made
haplotype analysis difﬁcult, according to linkage analysis data,
this pedigree can be considered a probable PKD3 family.
Forensic testing conﬁrmed the relationship between the family
members.
Mutation screening of the entire PKD2 gene was performed
for better evaluation of the family. Sequencing of all exons and
exon boundaries in the proband revealed a splice site mutation,
c.1094þ1G>A, Ala365fs, in intron 4, which results in a frame-
shift change after alanine 365 (Fig. 2A). The mutation possibly
produces the truncated protein, which results in a loss-of-
function effect. It is classiﬁed as deﬁnitely pathogenic according
to the ADPKD Mutation Database (http://pkdb.mayo.edu/cgi).
This mutation was also described in 1 Korean [19] and 1 French
family [9] previously. We also identiﬁed 1 synonymous variant
in exon 1, c.420G>A, p.G140G, alongwith 2 intronic and 130UTR
(untranslated region) variants (Table 3). Designing longer PCR
amplicons made it possible to identify deep intronic and un-
translated regions' variants.
Correct segregation of the mutation with the disease was
conﬁrmed by analyzing 2 healthy and 4 clinically affected (1Figure 2. The Sanger sequencing electropherograms. Proband with
heterozygous mutation c.1094þ1G>A (A). Individual III-3 with normal al-
leles (B).
Table 3. Polymorphism identiﬁed in PKD2 gene
Location Alterat
Genomic Gene cDNA
chr4:88008153 Exon 1 c.G420A
chr4:88008301 Exon 1 c.G568A
chr4:88038229 IVS 4 c.844-22G>A
chr4:88051854 IVS 7 c.1549-137T>C
chr4:88075950 30UTR c.*256C>T
cDNA, complementary DNA; IVS, intervening sequence; PKD, polycystic kidnmen and 3women) individuals including the IV-2. The proband
semi-aunt (III-3) shows 2 normal alleles (Fig. 2B).
Once more (PND), precise inspection of haplotypes pro-
posed the probability of 1 crossing over between the PKD2
intragenic and the adjacent downstream marker (D4S2929) in
the III-6 individual. At ﬁrst glance, it seems that his affected son
inherited the normal maternal haplotype (Fig. 1). Actually, the
occurrence of crossing over in the mother could not be distin-
guished easily because of the homozygosity of the ﬁrst 2 mi-
crosatellitemarkers, despite their high heterozygosity (Table 1).
Discussion
Herein, we evaluated the ADPKD family that ﬁrst appeared
to be unlinked to both PKD1 and PKD2 genes because of
recombination and identiﬁed the pathogenic mutation
(c.1094þ1G>A, Ala365fs) in all affected members. In addition,
we showed the worthiness of mutation detection in ADPKD
diagnosis, especially in mildly symptomatic individuals of PKD2
families.
Haplotype segregation analysis of polymorphic microsatel-
lite markers is an efﬁcient methodology. Besides various ap-
plications, it is used as the indirect genetic diagnosis tool in
heterogeneous genetic disorders, before or along with direct
mutation detection.
By linkage analysis, the responsible gene can be determined
without the need to detect the causative mutations, but this
approach needs the cooperation of other affected and unaf-
fected members of the family, and it cannot be used in sporadic
cases. In addition, the clinical states of all the participants must
be established deﬁnitively. In comparison to the challenging
procedure of PKD1 and PKD2 mutation screening, linkage
analysis will reduce the time and expense of analysis, which is
more prominent in PKD2-linked pedigrees. Furthermore, it is
recommended in PGD and prenatal genetic diagnosis for
detecting maternal contamination and as a second method to
conﬁrm the results [20]. Nevertheless, there are different fac-
tors that can confuse the analysis. Here, we mentioned the
most important ones.
First of all, microsatellite genotyping itself encountered
some challenges including sizing precision, allele calling, and
the dye shift error [21]. Furthermore, there is another source
of error, allelic dropout, which is failure in ampliﬁcation of 1
or 2 alleles, resulting in mistaken report of homozygous
instead of heterozygous or missing data [22]. One solution is
repeating the procedure; so here, all homozygous results
were conﬁrmed by regenotyping. In regard to linkage
analysis, locus heterogeneity, clinical misdiagnosis, mosai-
cism, de novo mutations, and recombination encompass
the most important confounders. There are examples of
pedigrees unlinked to both PKD1 and PKD2 loci because ofion DbSNP rs# Zygosity
Protein
p.G140G rs2728118 Hetero
p.A190T rs117078377 Hetero
rs2725221 Homo
rs2728104 Hetero
rs2728121 Homo
ey disease.
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hypomorphic PKD1 alleles [24], mosaicism [25,26], and de
novo mutation.
In our pedigree, the noninheritance of the PKD2 common
haplotype in the individual IV-2 could be due to the non-
paternity, another reason which can cause discrepancy in the
familial segregation analysis. Therefore, the biological rela-
tionship within the family was investigated by an in-house
panel of 24 short tandem repeat markers.
Precise inspection revealed that occurrence of 1 recombi-
nation event between 2 adjacent maternal STR markers could
explain the observed haplotype in IV-2. Recombination events
could be distinguished easily in the case of heterozygosity of
all the STR markers and complete informativeness of the
pedigrees. Although the recombination rates vary over the
human genome, 1.55 cM/Mb is estimated in females. Selecting
closely, STR markers can reduce the chance of recombination.
Here, the physical distance of 2 adjacent markers was about
200 Kb, whereas according to the Marshﬁeld map, the genetic
distance to telomeric end was 96.2 cM for both markers
(http://research.marshﬁeldclinic.org). As we see, recombina-
tion can still be happening in spite of neighboring markers.
Therefore, more caution must be taken in interpreting the
haplotype data especially in the prenatal genetic diagnosis and
PGD cases.
Informativeness of haplotype analysis is a factor of micro-
satellite marker heterozygosity. Here, selecting additive ﬂank-
ing markers may increase the haplotype informativeness and
help distinguishing the recombination event. Meanwhile, there
is very little information about the heterozygosity of PKD2
ﬂanking STR markers in Iranian population; in addition,
selecting distant markers would increase the chance of
recombination itself.
The blood sample of II-4 was not available, although it can
reveal the beginning of the recombination event. She was
70 years old and was being dialyzed for 5 years. The late age of
end-stage renal disease (ESRD) in the family is consistent with
the milder characteristics of PKD2 gene. She was the only per-
son who reached the end-stage renal disease in the family. Her
affected son died at the age of 45 years because of stroke. No
more clinical data were accessible. There was no history of any
liver, bladder, prostate, or ovarian cysts. III-2 had taken medi-
cation for hypertension.
Individual III-3 was a 47-year-old woman with equivocal
ultrasound renal ﬁndings, normal liver (size and density), and
intact spleen, pancreas, and gall bladder. Although the sensi-
tivity of imaging techniques in ADPKD diagnosis is about 90%,
especially in mild PKD2 families [27], she did not match the
ultrasound criteria for inclusion of ADPKD [28]. Here, mutation
screening can unambiguously rule out the disease.
Because haplotype analysis obviously excluded linkage to
PKD1 gene, PKD2 direct mutation analysis was performed at the
ﬁrst step, which leads to the identiﬁcation of the pathogenic
mutation.
In conclusion, genomic recombination is one of the con-
founders that lead to misinterpretation of haplotype and link-
age data. Selecting closer or more intragenic markers,
whenever possible, as well as highly polymorphic markers,
could overcome misdiagnosis. In the case of confusing results,
direct mutation screening can identify the causative mutation
in the pedigree. Here, the splicing mutation c.1094þ1G>A in
PKD2 was detected as a pathogenic mutation in all affectedmembers of presumably unlinked PKD1 and PKD2 family.
Furthermore, genetic diagnosis can exclude the disease in 1
member with equivocal imaging results.
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